Literature DB >> 15861323

Anti-inflammatory properties of statins.

Sabine Steffens1, Francois Mach.   

Abstract

Increasing clinical and experimental evidence indicates that some beneficial effects of statins, known as efficient therapeutic agents in cardiovascular disease treatment, may result from their ability to modulate vascular and endothelial cell gene expression by mechanisms independent of cholesterol reduction. It has been shown that statins exhibit direct anti-inflammatory properties via inhibition of proinflammatory cytokine and chemokine secretion, as well as through adhesion molecule expression on leukocytes. Another important mechanism by which statins may modulate the immune response is inhibition of interferon gamma-induced expression of class II major histocompatibility complexes. Class II major histocompatibility complex expression is central to immune regulation in T cell-mediated autoimmune diseases, indicating a potential beneficial role of statins in these pathologies. Indeed, promising new preclinical data indicate that statins might be useful in the treatment of multiple sclerosis and rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15861323     DOI: 10.1055/s-2004-869599

Source DB:  PubMed          Journal:  Semin Vasc Med        ISSN: 1528-9648


  13 in total

Review 1.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

2.  Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.

Authors:  Tai Yi; Deepak A Rao; Paul C Y Tang; Yinong Wang; Lisa A Cuchara; Alfred L M Bothwell; Christopher M Colangelo; George Tellides; Jordan S Pober; Marc I Lorber
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

Review 3.  Anti-inflammatory therapeutics for the treatment of atherosclerosis.

Authors:  Israel F Charo; Rebecca Taub
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

Review 4.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

5.  Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study.

Authors:  Annick Alpérovitch; Tobias Kurth; Marion Bertrand; Marie-Laure Ancelin; Catherine Helmer; Stéphanie Debette; Christophe Tzourio
Journal:  BMJ       Date:  2015-05-19

6.  Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells.

Authors:  Damelys Calderon; Valérie Planat-Benard; Valérie Bellamy; Valérie Vanneaux; Chantal Kuhn; Severine Peyrard; Jérôme Larghero; Michel Desnos; Louis Casteilla; Michel Pucéat; Philippe Menasché; Lucienne Chatenoud
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

Review 7.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

8.  Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures.

Authors:  Steve O'Hagan; Douglas B Kell
Journal:  J Cheminform       Date:  2017-03-09       Impact factor: 5.514

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

10.  In Vitro Transformation of Human Bronchial Epithelial Cells by Diesel Exhaust Particles: Gene Expression Profiling and Early Toxic Responses.

Authors:  Iselin Rynning; Jiri Neca; Kristyna Vrbova; Helena Libalova; Pavel Rossner; Jørn A Holme; Kristine B Gützkow; Anani K Johnny Afanou; Yke J Arnoldussen; Eva Hruba; Øivind Skare; Aage Haugen; Jan Topinka; Miroslav Machala; Steen Mollerup
Journal:  Toxicol Sci       Date:  2018-11-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.